Emergent underway with $100M in manufacturing upgrades as it gears up for ‘post-pandemic work’
After struggling through COVID-19 vaccine production woes in 2021, Emergent BioSolutions has another surprise for its investors in early 2022. Last month, Emergent projected revenues of $1.4 billion to $1.5 billion for this year. Now, the company has dropped the figure to $1.3 to $1.4 billion. Why the adjustment? In its quarterly report, Emergent credited its decision to…